.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
McKinsey
QuintilesIMS
Federal Trade Commission
Colorcon
Chinese Patent Office
Deloitte
US Department of Justice
Medtronic

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Subscribe

« Back to Dashboard

Details for Patent: ➤ Subscribe

Title:Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Abstract: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}ac- etamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- -fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Inventor(s): Dumble; Melissa (Collegeville, PA), Kumar; Rakesh (Collegeville, PA), Laquerre; Sylvie (Collegeville, PA), Lebowitz; Peter (Collegeville, PA)
Assignee: GlaxosmithKline LLC (Philadelphia`, PA)
Filing Date:Mar 05, 2014
Application Number:14/197,421
Claims:1. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00025## or a pharmaceutically acceptable salt or solvate thereof; and (ii) a compound of formula (II) ##STR00026## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein compound (I) is in the form of the dimethyisulfoxide solvate.

3. The method of claim 1, wherein compound (II) is in the form of the methanesulfonate salt.

4. The method of claim 1, wherein the non-small cell lung cancer is BRAF V600E mutant non-small cell lung cancer.

5. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00027## or a pharmaceutically acceptable salt thereof; and (ii) a compound of formula (II) ##STR00028## or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fuji
Chubb
Chinese Patent Office
Express Scripts
Novartis
Covington
Farmers Insurance
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot